The revenue beat and narrowing loss are positive, but the EPS miss and pre-revenue pipeline stage keep the stock range-bound. Key catalysts are the FG-3246 interim analysis in Q4 2026 and roxadustat Phase 3 start in H2 2026 — traders should watch for enrollment updates and FDA feedback on the roxadustat protocol.
Price Chart
Executive Summary
Kyntra Bio reported Q1 2026 revenue of $3.7M (above $1.6M consensus) but EPS of -$3.74 missed the -$3.35 consensus by 11.6%. The company highlighted steady enrollment in its Phase 2 FG-3246 trial (interim analysis on track for Q4 2026) and finalizing the Phase 3 roxadustat protocol for LR-MDS. Cash of $100.3M provides runway into 2028, but the EPS miss and ongoing operating losses temper the positive pipeline updates.
Key Financial Metrics
Key Facts
- Q1 2026 total revenue $3.7M vs $2.7M YoY (above $1.6M consensus)
- GAAP EPS -$3.74 vs consensus -$3.35 (miss by 11.6%)
- Net loss from continuing ops $15.1M vs $16.8M YoY (narrower loss)
- Cash, equivalents, investments, and AR of $100.3M as of March 31, 2026
- Phase 2 FG-3246 mCRPC trial interim analysis on track for Q4 2026
- Phase 3 roxadustat protocol for LR-MDS being finalized; trial initiation H2 2026
- Cash runway expected into 2028
Financial Impact
Revenue beat of $2.1M vs consensus; EPS miss of $0.39 vs consensus; operating loss narrowed by $1.1M YoY
Risk Factors
- EPS miss of 11.6% vs consensus could pressure the stock near-term
- Pre-revenue pipeline with no approved products in the US
- Dependence on FG-3246 Phase 2 data and roxadustat regulatory path
- Negative stockholders' equity of -$43.8M and total deficit of -$30.8M
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3292303 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 20d ago | 3 | $6.13 $5.57 | ▼ −9.22% | ▼ −8.24% | $4.50 (−26.59%) |
Oct 6, 2026 21d ago | 8-K | $6.13 $5.57 | ▲ +9.22% | ▲ +8.24% | $4.50 (+26.59%) |
Oct 1, 2026 26d ago | 8-K | $6.50 $5.96 | ▼ −8.31% | ▼ −9.61% | $4.50 (−30.77%) |
Jun 9, 2026 20w ago | 8-K | $6.69 $6.91 | ▲ +3.29% | ▼ −0.14% | $4.50 (−32.74%) |
May 11, 2026 24w ago | Press Release | $7.23 $6.83 | ▼ −5.47% | ▼ −5.54% | $4.50 (−37.72%) |
Mar 16, 2026 32w ago | Press Release | $7.37 $6.75 | ▲ +8.41% | ▲ +5.76% | $4.50 (+38.94%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers